

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION AGREEMENT WITH
SHANGHAI SHENQI MEDICAL TECHNOLOGY CO., LTD.
TO ADVANCE THE COMMERCIALISATION OF
THE BIOHEART® BIOABSORBABLE
RAPAMYCIN-ELUTING CORONARY STENT SYSTEM**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that the Company has recently entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with Shanghai Shenqi Medical Technology Co., Ltd. (“**Shenqi Medical**”) to jointly advance the commercialisation and clinical application of the Bioheart® Bioabsorbable Rapamycin-Eluting Coronary Stent System (the “**BioHeart Stent**”), an independently developed product of the Company.

About the Strategic Cooperation Agreement

Under the Strategic Cooperation Agreement, both parties will fully leverage their respective resource advantages in market channel development and academic promotion to jointly advance the commercialisation and clinical application of the BioHeart Stent. The Board considers that the Strategic Cooperation Agreement will further integrate innovative products with professional market service resources and jointly promote the clinical popularisation and standardised application of the BioHeart Stent as an innovative “interventional treatment without implantation” solution, providing patients with coronary heart disease with more treatment options.

About the BioHeart Stent

The BioHeart Stent is a new-generation bioabsorbable rapamycin-eluting coronary stent system independently developed by the Company. Adopting an ultra-thin strut design with a minimum strut thickness of 90 µm, the BioHeart Stent enhances radial support while improving device deliverability and lesion crossing capability. The stent backbone is made of poly-L-lactic acid (PLLA) material, which can be gradually degraded and absorbed in vivo and gradually disappears from the vessel after completing its staged support mission, truly realising the treatment philosophy of “interventional treatment without implantation”. Meanwhile, the BioHeart Stent features a poly-D, L-lactic acid (PDLLA) sustained-release coating loaded with sirolimus, which effectively inhibits neointimal hyperplasia through sustained drug release and supports long-term luminal stability. Multi-tiered clinical studies have also provided clinical support for the safety and efficacy of the BioHeart Stent.

About Shenqi Medical

Shenqi Medical was established in September 2014, with its headquarters in Shanghai, China. It is an innovative medical device enterprise integrating research and development, manufacturing and sales, with a product portfolio covering cardiovascular intervention, structural heart disease and peripheral vascular intervention. The Board believes that Shenqi Medical’s market channels and academic promotion resources in the field of cardiovascular intervention will facilitate the commercialisation and clinical application of the BioHeart Stent. To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, Shenqi Medical and its ultimate beneficial owner(s) are third parties independent of the Company and its connected person(s) (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

Reasons for and Benefits of Entering into the Strategic Cooperation Agreement

The Board believes that entering into the Strategic Cooperation Agreement between the Company and Shenqi Medical represents an important step for the Company in advancing its commercialisation process and accelerating the market adoption of its products. The Board considers that the Strategic Cooperation Agreement is in line with the Company’s business development strategy and is in the interests of the Company and its shareholders as a whole.

General

The Strategic Cooperation Agreement is a framework and non-binding agreement that sets out the parties' intentions and basic principles for cooperation. As at the date of this announcement, no formal or legally binding agreement in relation to the cooperation has been entered into between the parties. As such, the cooperation may or may not be materialised. Further announcement(s) will be made by the Company as and when appropriate to inform shareholders and potential investors of the Company of the further development of the cooperation.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive Director

Shanghai, the People's Republic of China, September 15, 2026

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive Director, Mr. Yunqing WANG and Ms. Peili WANG as executive Directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive Directors.